Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 1,064 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $51,306.08. Following the completion of the sale, the senior vice president now owns 4,232 shares in the company, valued at approximately $204,067.04. The trade was a 20.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Jolanda Howe also recently made the following trade(s):

• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total value of $117,750.00.

Mirum Pharmaceuticals Trading Down 0.3 %

NASDAQ:MIRM traded down $0.17 on Friday, reaching $51.06. The company's stock had a trading volume of 616,405 shares, compared to its average volume of 532,217. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $53.49. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market cap of $2.45 billion, a PE ratio of -25.28 and a beta of 0.96. The business's 50-day moving average price is $44.80 and its two-hundred day moving average price is $42.31.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's quarterly revenue was up 89.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.57) earnings per share. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP raised its holdings in Mirum Pharmaceuticals by 35.9% during the second quarter. Marshall Wace LLP now owns 20,520 shares of the company's stock worth $702,000 after acquiring an additional 5,420 shares in the last quarter. Creative Planning bought a new stake in Mirum Pharmaceuticals during the third quarter worth about $249,000. Hennion & Walsh Asset Management Inc. raised its holdings in Mirum Pharmaceuticals by 10.8% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 116,054 shares of the company's stock worth $4,526,000 after acquiring an additional 11,284 shares in the last quarter. Values First Advisors Inc. raised its holdings in Mirum Pharmaceuticals by 20.1% during the third quarter. Values First Advisors Inc. now owns 23,725 shares of the company's stock worth $925,000 after acquiring an additional 3,971 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock worth $67,000 after acquiring an additional 318 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. HC Wainwright reaffirmed a "buy" rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup lifted their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, Leerink Partners lifted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.